Merck Share Holder Equity 2010-2024 | MRK

Merck share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Merck share holder equity for the quarter ending September 30, 2024 was $43.648B, a 12.66% increase year-over-year.
  • Merck share holder equity for 2023 was $37.635B, a 18.29% decline from 2022.
  • Merck share holder equity for 2022 was $46.058B, a 20.39% increase from 2021.
  • Merck share holder equity for 2021 was $38.257B, a 50.59% increase from 2020.
Merck Annual Share Holder Equity
(Millions of US $)
2023 $37,635
2022 $46,058
2021 $38,257
2020 $25,404
2019 $26,001
2018 $26,882
2017 $34,569
2016 $40,308
2015 $44,767
2014 $48,791
2013 $52,326
2012 $55,463
2011 $56,943
2010 $56,805
2009 $61,485
Merck Quarterly Share Holder Equity
(Millions of US $)
2024-06-30 $43,648
2024-03-31 $40,424
2023-12-31 $37,635
2023-09-30 $41,300
2023-06-30 $38,742
2023-03-31 $46,905
2022-12-31 $46,058
2022-09-30 $44,524
2022-06-30 $43,318
2022-03-31 $40,953
2021-12-31 $38,257
2021-09-30 $35,863
2021-06-30 $33,388
2021-03-31 $27,039
2020-12-31 $25,404
2020-09-30 $29,270
2020-06-30 $27,744
2020-03-31 $26,300
2019-12-31 $26,001
2019-09-30 $26,925
2019-06-30 $27,737
2019-03-31 $27,670
2018-12-31 $26,882
2018-09-30 $32,656
2018-06-30 $32,766
2018-03-31 $33,901
2017-12-31 $34,569
2017-09-30 $38,499
2017-06-30 $39,712
2017-03-31 $40,088
2016-12-31 $40,308
2016-09-30 $43,957
2016-06-30 $43,446
2016-03-31 $43,901
2015-12-31 $44,767
2015-09-30 $45,679
2015-06-30 $46,638
2015-03-31 $47,917
2014-12-31 $48,791
2014-09-30 $45,360
2014-06-30 $48,516
2014-03-31 $52,564
2013-12-31 $52,326
2013-09-30 $50,006
2013-06-30 $50,105
2013-03-31 $55,606
2012-12-31 $55,463
2012-09-30 $58,212
2012-06-30 $57,673
2012-03-31 $57,314
2011-12-31 $56,943
2011-09-30 $57,596
2011-06-30 $57,922
2011-03-31 $56,839
2010-12-31 $56,805
2010-09-30 $58,048
2010-06-30 $57,666
2010-03-31 $60,343
2009-12-31 $61,485
2009-09-30 $25,349
2009-06-30 $22,737
2009-03-31 $22,002
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $258.042B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69